Interestingly, the treatment of multiple myeloma cells with the anticancer BRD4 inhibitor JQ1 resulted in the preferential loss of BRD4 at the SE, prompting transcriptional elongation defects that preferentially affect genes with SEs, such as MYC oncogene [54]. This evidence concerns the gene BRD4 and plasma cell myeloma.